Scope of the Study
Cell encapsulation is the primary machinery for cell based therapeutic delivery system. Live cell encapsulation technology is used for immobilization of cells within the semipermeable membrane. The technique provides significant advantages as compared to protein encapsulation. The encapsulation of cells is used to allow the delivery of molecules of interest for a longer time as cells used to release these molecules of interest continuously. Further, ongoing technological advancements in live cell encapsulation and increasing public awareness about the clinical role of encapsulated cells in disease management is driving the global live cell encapsulation market.
The market study is being classified by Type (Alginate, HEMA-MMA [Hydroxyethyl Methacrylate-methyl Methacrylate], Siliceous Encapsulates, Cellulose Sulfate, PAN-PVC [Acrylonitrile Vinyl Chloride] and Others), by Application (Probiotics, Transplant, Drug Delivery and Research) and major geographies with country level break-up. According to AMA, the Global Live Cell Encapsulation market is expected to see growth rate of 3.2% and may see market size of USD302.01 Million by 2024.
BioTime, Inc. (United States), Reed Pacific Pty Ltd. (Australia), Viacyte, Inc. (United States), Neurotech Pharmaceuticals, Inc. (United States), Living Cell Technologies Ltd. (Australia), Merck KGAA (Germany), Sigilon Therapeutics, Inc. (United States), Encapsys, LLC (United States), Evonik Industries (Germany), Lycored (Israel) and MiKroCaps (Slovenia) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are PharmaCyte Biotech, Inc. (United States), BCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), Sernova Corporation (Canada) and Balchem Corporation (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Live Cell Encapsulation market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Live Cell Encapsulation market by Type, Application and Region.
On the basis of geography, the market of Live Cell Encapsulation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2018. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement. If we see Market by Manufacturing Technique, the sub-segment i.e. Simple Dripping will boost the Live Cell Encapsulation market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increasing Number of Target Patient Population
- Growing Public & Private Investments in the field of Live Cell Encapsulation
- Rising Clinical Data for the Efficacy of Cell Encapsulation Techniques
- Increasing Adoption of Novel Drug Delivery System for the Treatment of Acute & Chronic Disease
- Limited Availability of High Quality Raw Materials
- Lack of Skilled Professionals, Ethical & Legal Issues
- Increasing Investments for the Development of Novel Therapeutics
- Significant Adoption of Alternative Therapies is posing a Challenge for the Market
Market Leaders and their expansionary development strategies
January 2019, PharmaCyte Biotech, Inc. a biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box PharmaCyte’s partner, Austrianova, has successfully encapsulated the live cells used in PharmaCyte’s therapy for its planned clinical trial in patients with locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC). The cells are now growing and dividing inside the Cell-in-a-Box capsules.
In August 2018, Balchem Italia S.r.l., a wholly owned subsidiary of Balchem Corporation, acquired Bioscreen Technologies, S.r.l., a privately held manufacturer of encapsulated and fermented feed nutrition ingredients. With this, the company aims to expand its position in the market.
Key Target AudienceResearch Organizations, Potential Investors, Downstream Vendors, Industrial Association, Government and Regulatory Bodies and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase